• SPONTAN Phase II pharmacokinetic study recruitment complete; interim PK data expected Q2 CY2026
• SPONTAN Phase I data accepted for podium presentation at the World Meeting on Sexual Medicine 2026
• SPONTAN continues to demonstrate positive real-world outcomes, including in younger men

LTR Pharma Limited (ASX:LTP) has provided an update on its quarterly activities and Appendix 4C cash flow report for the period ending 31 March 2026. Key highlights include:- SPONTAN Phase II pharmacokinetic study recruitment complete, with dosing of the final cohort advanced during the quarter. Interim PK data is expected in Q2 CY2026.- Phase I SPONTAN data accepted for podium presentation at the World Meeting on Sexual Medicine 2026, providing international scientific validation.- SPONTAN continues to demonstrate positive real-world outcomes, including in younger men with performance-related erectile difficulties.- ROXUS US commercial partner discussions progressing via the FDA 503(a) personalised medicine pathway.- Cash balance of A$24.1 million at 31 March 2026, debt-free, supporting upcoming clinical readouts, US commercial strategy execution, and regulatory development.The company maintained a strong financial position during the quarter, with a cash runway of approximately 13 quarters based on current operating cash outflows. Payments to related parties totalled A$168,000, comprising director fees, salary and superannuation.

The company is focused on executing its planned activities, including the SPONTAN Phase II pharmacokinetic data readout in Q2 CY2026, progression of ROXUS commercial preparations, the human factors and leachables studies, and continued real-world evidence generation through the Australian SAS programme.